Pelthos Therapeutics, Inc. (PTHS)
22.35
+0.16
(+0.72%)
USD |
NYAM |
Sep 28, 16:00
22.35
0.00 (0.00%)
After-Hours: 16:40
Pelthos Therapeutics Research and Development Expense (TTM) : 1.305M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.305M |
| March 31, 2026 | 1.220M |
| December 31, 2025 | 1.228M |
| September 30, 2025 | 1.269M |
| June 30, 2025 | 1.137M |
| March 31, 2025 | 1.088M |
| September 30, 2024 | 3.188M |
| Date | Value |
|---|---|
| June 30, 2024 | 2.823M |
| March 31, 2024 | 2.860M |
| December 31, 2023 | 2.579M |
| September 30, 2023 | 0.5798M |
| June 30, 2023 | 0.5586M |
| March 31, 2023 | 0.5353M |
| December 31, 2022 | 0.3917M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Travere Therapeutics, Inc. | 227.14M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |
| Savara, Inc. | 86.84M |